imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
flucohexal 150 mg kemény kapszula
hexal ag - flukonazol -
mycosyst 2 mg/ml oldatos infúzió
richter gedeon nyrt. - flukonazol -
diflazon 2 mg/ml oldatos infúzió
krka d.d., - flukonazol -
fluconazole kabi 2 mg/ml oldatos infúzió
fresenius kabi hungary kft. - flukonazol -
fluconazol vitabalans 150 mg tabletta
vitabalans oy - flukonazol -
clarithromycin 1 a pharma 250 mg filmtabletta
1 a pharma gmbh - klaritromicin -
clarithromycin 1 a pharma 500 mg filmtabletta
1 a pharma gmbh - klaritromicin -
fromilid uno 500 mg retard filmtabletta
krka d.d., - klaritromicin -
fromilid 250 mg filmtabletta
krka d.d., - klaritromicin -